CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Shawn F. Johnson, Cristina Cruz, Ann Katrin Greifenberg, Sofia Dust, Daniel G. Stover, David Chi, Benjamin Primack, Shiliang Cao, Andrea J. Bernhardy, Rhiannon Coulson, Jean Bernard Lazaro, Bose Kochupurakkal, Heather Sun, Christine Unitt, Lisa A. Moreau, Kristopher A. Sarosiek, Maurizio Scaltriti, Dejan Juric, José Baselga, Andrea RichardsonScott Rodig, Alan D. D'Andrea, Judith Nã Balma, Neil Johnson, Matthias Geyer, Violeta Serra, Elgene Lim, Geoffrey I. Shapiro

Nuclear Dynamics and Cancer (NDC)
Cancer Epigenetics Institute

Harvard University
Dana-Farber Cancer Institute
Vall d'Hebron Institute of Oncology
Autonomous University of Barcelona
University of Bonn
Max Planck Insitute for Neurobiology of Behavior - CAESAR
Ohio State University
Brigham and Women's Hospital
Washington University St. Louis
Boston Children's Hospital
Fox Chase Cancer Center
Kinghorn Cancer Centre
Memorial Sloan-Kettering Cancer Center
Massachusetts General Hospital Cancer Center
Johns Hopkins University
Biomedical Network on Rare Diseases (CIBERER)
University Hospital
Vall d'Hebron Institute OfOncology

Research output: Contribution to journal › Article › peer-review

224 Scopus citations

Sort by
Weight
Alphabetically

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Fingerprint

Biochemistry, Genetics and Molecular Biology

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science